Summit Therapeutics SMMT Proceeds From Warrant Exercises
Proceeds From Warrant Exercises at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's proceeds from warrant exercises.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's proceeds from warrant exercises?
- Summit Therapeutics (SMMT) reported proceeds from warrant exercises of $0 in Q1 2026.
- How has Summit Therapeutics's proceeds from warrant exercises changed year-over-year?
- Summit Therapeutics's proceeds from warrant exercises decreased by 100.0% year-over-year, from $5.66M to $0.
- What does proceeds from warrant exercises mean?
- Cash received when investors exercise their rights to buy shares via warrants.
- How do you interpret proceeds from warrant exercises?
- Higher proceeds indicate that the stock price is performing well enough to incentivize warrant holders to convert, providing a source of non-dilutive capital.
- How does proceeds from warrant exercises compare across companies?
- Common in companies that have previously issued warrants as part of financing packages; peers report this as a component of financing cash flow.